Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall

Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology expertise HAMBURG, DE / ACCESS Newswire / May 4, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the nomination of a small molecule preclinical development candidate (PDC) from its multi‑target drug discovery alliance in medical dermatology with Almirall S.A. The program is aimed at developing novel treatments for immune‑mediated inflammatory skin diseases with high unmet medical need.